Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165482 | 0.87 | KCNJ1 (0.52) | KCNJ1ALDH1A1NNMTTHRB | |
| SCHEMBL31058098 | 0.78 | KCNJ1 (0.46) | KCNJ1ALDH1A1NNMT | |
| SCHEMBL4927935 | 0.76 | KCNJ1 (0.44) | KCNJ1ALDH1A1NNMT | |
| SCHEMBL21935846 | 0.76 | KCNJ1 (0.44) | KCNJ1ALDH1A1NNMTTHRB | |
| SCHEMBL3603082 | 0.76 | KCNJ1 (0.44) | KCNJ1ALDH1A1NNMTTHRB | |
| SCHEMBL5302622 | 0.74 | KCNJ1 (0.43) | KCNJ1ALDH1A1NNMT | |
| SCHEMBL19360076 | 0.74 | KCNJ1 (0.43) | KCNJ1ALDH1A1NNMT | |
| SCHEMBL30508771 | 0.74 | KCNJ1 (0.43) | KCNJ1ALDH1A1NNMT | |
| SCHEMBL1070960 | 0.74 | JUN (0.44) | KCNJ1ALDH1A1NNMT | |
| SCHEMBL19360077 | 0.74 | KCNJ1 (0.43) | KCNJ1ALDH1A1NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754743-B2 | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | MSD K.K. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-7432287-B2 | Heteroarylcarbamoylbenzene derivative | BANYU PHARMECEUTICAL CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | GCK, GCKR, KHK | KCNJ1 93/4885ALDH1A1 707/4885NNMT 2218/4885 |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | GCK, GCKR, GALK1 | KCNJ1 355/4885ALDH1A1 902/4885NNMT 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.